1 / 42

Pharmacological management Blood glucose-lowering medicines

Pharmacological management Blood glucose-lowering medicines. Aims of treatment. Reduce the symptoms of hyperglycaemia Limit adverse effects of treatment Maintain quality of life and psychological well-being Prevent or delay vascular complications of diabetes. 0. 3. 6. 9. 12. 15.

javen
Download Presentation

Pharmacological management Blood glucose-lowering medicines

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Pharmacological managementBlood glucose-lowering medicines Slides current until 2008

  2. Aims of treatment • Reduce the symptoms of hyperglycaemia • Limit adverse effects of treatment • Maintain quality of life and psychological well-being • Prevent or delay vascular complications of diabetes Slides current until 2008

  3. 0 3 6 9 12 15 UKPDS:long-term glucose control 9 Conventional 8 HbA1c (%) Intensive 7 6 0 Years of treatment UKPDS Study Group 1998 Slides current until 2008

  4. Natural history of type 2 diabetes Henry 1998 Slides current until 2008

  5. Mechanisms of action GLP-1 (incretins) improve response to glucose level Biguanides and thiazolidinediones reduce glucose production Insulin secretagogues: sulphonylureas and meglitinides increase insulin production Alpha-glucosidase inhibitors slow absorption of sucrose and starch Thiazolidinediones and biguanides reduce insulin resistance Slides current until 2008

  6. Understanding the names • Chemical name relates to chemical structure • Generic name identifies a unique compound with therapeutic properties • Brand name given by the manufacturer Slides current until 2008

  7. What are the most common oral blood glucose-lowering medicines in your community? • What are their brand names and generic names? Slides current until 2008

  8. The principles of combination therapy • Two (or more) oral blood glucose-lowering medicines that have different mechanisms of action • Two medications rather than increase in initial medicine to maximum dosage • Fewer side effects than mono-therapy at higher doses Slides current until 2008

  9. Expected effect of blood glucose-lowering medicines Canadian Diabetes Association 2003 Slides current until 2008

  10. Strategies to help people remember • Check that people understand how and when to take their medicines • Clarify the benefits of treatment • Keep regimens simple • Minimize costs • Discuss adverse effects Rubin 2005 Slides current until 2008

  11. Targets for blood glucose 1CDA 2003, 2ADA 2004, 3 IDF 2005 Slides current until 2008

  12. Suggested starting medicine CDA 2003 Slides current until 2008

  13. Increasing or adding • If goals have not been reached within 2-3 months, medication should be increased or medication from a different class added • Target levels should be reached within 6 months • Insulin should be added if necessary to reach target levels Slides current until 2008

  14. Biguanides • Action not fully understood • Decreases glucose production in liver • Mild and variable effect on muscle sensitivity to insulin Side effects • Gastrointestinal (nausea, abdominal discomfort or diarrhea and occasional constipation) • Lactic acidosis Slides current until 2008

  15. Biguanides Contraindications • Renal insufficiency • Liver failure • Heart failure • Severe gastrointestinal disease Advantages • Do not cause hypoglycaemia when used as mono-therapy • Do not cause weight gain; may contribute to weight loss Slides current until 2008

  16. Biguanides First-line treatment in overweight or obese people • Do not cause weight gain • Have some effect on resistance at the periphery Slides current until 2008

  17. Biguanides Caution • Should be discontinued 24 hours before procedures requiring intravenous contrast dye • Can be restarted 48 hours after the procedure if renal function is not compromised Slides current until 2008

  18. Sulphonylureas • Increase insulin secretion regardless of blood glucose levels • Many different medicines in this class Side effects • Hypoglycaemia • Stimulate appetite and provoke weight gain • Nausea, fullness, heartburn • Occasional rash • Swelling Slides current until 2008

  19. Sulphonylureas Short-acting secretagogues Meglitinides – increase insulin secretion in response to increasing blood glucose levels (i.e. after eating) Side effects • Hypoglycaemia (probably less than sulphonylureas) • Weight gain Slides current until 2008

  20. Sulphonylureas Contraindications • Type 1 diabetes • Pregnancy • Breastfeeding Sulphonylureas - Use cautiously with liver or kidney disease Meglitinides - Severe impairment of liver function Slides current until 2008

  21. Sulphonylureas Things to remember • Some sulphonylureas have slower onset and lower peak than glyburide, thus may provoke less hypoglycaemia • Some need to be taken only once a day, therefore may be easier to remember to take • First generation sulphonylureas, such as chlorpropamide may accumulate and cause hypoglycaemia due to their long duration of action Slides current until 2008

  22. Thiazolidinediones • Improve sensitivity to insulin in muscle, adipose tissue and liver • Reduce glucose output from liver • Changes fat distribution by decreasing visceral fat and increasing peripheral fat Side effects • Weight gain, fluid retention • Upper respiratory infection and headache • Decrease in haemoglobin Slides current until 2008

  23. Thiazolidinediones Contraindications • Liver disease, heart failure or history of heart disease • Pregnancy and breast feeding They are not contraindicated in renal insufficiency Potential benefits • Reduced levels of LDL-cholesterol and increased level of HDL-cholesterol Slides current until 2008

  24. Alpha glucosidase inhibitors • Slow digestion of sucrose and starch and therefore delay absorption • Slow post-meal rise in blood glucose Side effects • Flatulence, abdominal discomfort , diarrhoea • As mono-therapy will not cause hypoglycaemia • Hypoglycaemia when used with other medicine (e.g. a sulphonylurea) Slides current until 2008

  25. Alpha glucosidase inhibitors Contraindications • Intestinal diseases, such as Crohn’s • Autonomic neuropathy affecting the gastro-intestinal tract Must be taken just before a meal Slides current until 2008

  26. GLP-1 (incretin mimetic agent) • Improves beta-cell responsiveness to increasing glucose levels • Decreases glucagon secretion • Slows gastric emptying • Results in a feeling of fullness • Must be injected subcutaneously twice a day, within 30-60 minutes before a meal • Reduces HbA1c by ~1% Side effects • Nausea • Weight loss • Diarrhoea • Risk of hypoglycaemia when used with a sulphonylurea Slides current until 2008

  27. GLP-1 (incretin mimetic agent) Contraindications • End-stage kidney disease or renal impairment • Pregnancy • Severe gastrointestinal disease Slides current until 2008

  28. DPP-4 InhibitorsA new class of medications called DPP-4 inhibitors help improve A1C without causing hypoglycemia. They work by by preventing the breakdown of a naturally occuring compound in the body, GLP-1. GLP-1 reduces blood glucose levels in the body, but is broken down very quickly so it does not work well when injected as a drug itself. By interfering in the process that breaks down GLP-1, DPP-4 inhibitors allow it to remain active in the body longer, lowering blood glucose levels only when they are elevated. DPP-4 inhibitors do not tend to cause weight gain and tend to have a neutral or positive effect on cholesterol levels. Sitagliptin(Januvia), saxagliptin(Onglyza) and Vidagliptin(Galvus) are currently DPP-4 inhibitors on the market .ADA Slides current until 2008

  29. Older people with diabetes Beware of the possible reductions in • General good health (with other concomitant conditions) • Kidney function (and increased risk of hypoglycaemia) • Family support and monitoring • Vision • Flexibility and activities of daily living Remember also • Poly-pharmacy increases the risk of medicine-related adverse events • To review all medication and complementary therapies Slides current until 2008

  30. Older people with diabetes • Always start with the lowest dose of any blood glucose-lowering medicine and increase gradually • Using shorter-acting medicines reduces the risk of hypoglycaemia • Hypoglycaemia may increase the risk of falls and heart attack in older people Slides current until 2008

  31. Older people with diabetes Remember the possibility of • Forgetfulness • Poor motivation • Depression • Cognitive deficits • Poly-pharmacy • Reduced manual dexterity These impact on the ability to maintain self-care and achieve maximum benefits from blood glucose-lowering medicines. Slides current until 2008

  32. Ineffectiveness of blood glucose-lowering medicines If oral blood glucose-lowering medicines are ineffective • Check diet and exercise • Consider adding intermediate or long-acting insulin at bedtime • Maintain metformin • Consider reducing or stopping the morning sulphonylurea Slides current until 2008

  33. Slides current until 2008

  34. Case study • AB has had type 2 diabetes for two years • 51-year-old truck driver • BMI of 32, blood pressure at 150/95 • HbA1C 9.5% • No medication • AB says he has no time for exercise and will not change his meal pattern What medication do you think should be started and why? Slides current until 2008

  35. Summary • Lifestyle changes first • Start medicine as soon as needed • Add a different kind • No delay starting insulin Slides current until 2008

  36. Review question 1. Which of the following adverse reactions are most likely due to metformin therapy? • Oedema • Diarrhea • Heart failure • Weight gain Slides current until 2008

  37. Review question 2. Which of the following statements best describes alpha-glucosidase inhibitors? • Likely to cause weight gain • Should be taken with first bite of the meal • Commonly associated with hypoglycaemia • Well tolerated, few side effects Slides current until 2008

  38. Review question 3. Which statement is FALSE? • All oral medicines used to treat diabetes should be discontinued once insulin is started • In most people, blood glucose-lowering medicines become less effective over time • Blood glucose-lowering medicines from different classes are often used in combination to reach target blood glucose • It is important to be physically active and follow a prescribed meal plan in addition to blood glucose-lowering medicines Slides current until 2008

  39. Review question JL is a 45-year-old man. He has been taking 5 mg glyburide and 500 mg metformin at breakfast and supper. His fasting blood glucose ranges from 5.3–6.7mmol/L but he has been experiencing hypoglycaemia most days at 3 or 4 pm. 4. What is the likely cause of JL’s low blood sugars? • Breakfast metformin • Supper metformin • Breakfast glyburide • Supper glyburide Slides current until 2008

  40. Review question 5. When filling his prescription for a sulphonylurea, what is the most important thing to discuss with John? • What and when to eat • When to take the medication • How to recognize and treat hypoglycaemia • When to see his doctor again Slides current until 2008

  41. Answers • b • b • a • c • c Slides current until 2008

  42. References • UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in person with diabetes with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53. • Ahmann AJ, Riddle MC. Current blood glucose lowering medicines for type 2 diabetes. Postgrad Med 2002; 111(5): 32-46. • Henry RR. Type 2 diabetes care: the role of insulin-sensitizing agents and practical implications for cardiovascular disease prevention. Am J Med 1998; 105(1A): 20S-26S. • Luna B, Feinglos MN. Blood glucose-lowering medicines in the management of type 2 diabetes mellitus. Am Fam Physician2001; 63(9): 1747-56. • Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diab 2003; 27(supple 2). • Yki-Jarvinnen H, Ryysy L, Nikkila K, et al. Comparison of bedtime insulin regimen in person with diabetes with type 2 diabetes mellitus; a randomized control trial. Annals Intern Med1999; 130(5): 89-96. • Amylin Pharmaceuticals Inc and Eli Lilly & Co. Byetta (cited 2005July 25) (16 screens). (Available from: http://www.byetta.com) • Rubin Rr. Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Am J Med 2005; 118(5A): 275-345. Slides current until 2008

More Related